

Kilitch Drugs (India) Ltd.



14th August, 2014

To,
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex,
Bandra (E), Mumbai - 400 051.

Scrip Code: KILITCH

Sub: Outcome of Board Meeting held on Thursday, 14th August, 2014.

Respected Sir/Madam,

With reference to the above captioned subject, we wish to intimate your esteemed exchange that as decided in the Meeting of the Board of Directors of the Company held on Thursday, 14th August, 2014 at 3.00 p.m., for which intimation was already given to you, the Board of Directors has:

- Taken on record the Unaudited (Provisional) Financial Results for the Quarter ended June 30, 2014 along with Limited Review Report.
- Adopted and approved the Notice & Directors Report of the Company along with the Corporate Governance Report for financial year 2013-2014;
- Finalized the dates of Book Closure from **Thursday, September 25, 2014 to Tuesday, September 30, 2014 (both days inclusive)** for the purpose of forthcoming 22nd Annual General Meeting;
- Decided to convene 22nd Annual General Meeting of the Members of the Company on **Tuesday, 30th September, 2014 at 9.30 A.M.** at its Registered Office at C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701.
- Authorized Mr. Mukund Mehta, Managing Director of the Company, to oversee the entire E-voting Process at the 22nd AGM of the Company;
- Appointed Mr. Deep Shukla, Practicing Company Secretary as a Scrutinizer to conduct the entire voting Process at the 22nd AGM of the Company [including e-voting] and to submit the Report for declaration of the results thereof.



Admin Office : 37, Ujagar Industrial Estate, W.T.Patil Marg, Deonar, Mumbai - 400 088. • Tel.: +91-22-6121 4100 • Fax : +91-22-6703 1658

Regd. Office & Factory : C-301/2, M.I.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705, Maharashtra.

• Tel.: +91-22-6514 4185 / 2768 0913 • Fax : +91-22-2768 0912 • E-mail : info@kilitch.com • Website : www.kilitch.com

CONTINUATION SHEET

Further, we wish to inform the BSE that in terms of Section 108 of the Companies Act, 2013 and Rule 20(1) of the Companies (Management & Administration) Rules 2014, the Company will provide its Shareholders the facility to exercise their vote for transacting the items of ordinary and special business at the ensuing 22nd Annual General Meeting (AGM) to be held on September 30, 2014, by electronic means. The Company would be availing e-voting services of Central Depository Services (India) Limited (CDSL). Further pursuant to Rule 20(3)(vii) of the Companies (Management & Administration) Rules 2014, the Company has fixed August 27, 2014 as the cutoff date to determine the Shareholders (holding equity shares of the Company in both electronic and physical form) eligible to cast their vote for transacting the items of ordinary and special business at the ensuing 22nd AGM.

The above intimation is given to you pursuant to Clauses 16, 41 and other applicable Clauses of the Listing Agreement.

Thanking you,

Yours faithfully,


KILITCH DRUGS (INDIA) LIMITED
MURUND MEHTA
MANAGING DIRECTOR



KILITCH DRUGS (INDIA) LTD.

Corp. Off. : 37-41 Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088. Tel. : 6703 3322
Factory : C-301/2, T.T.C. Indl. Area, M. I. D. C., Pawane Village, Thane Maharashtra Tel. : 6514 4185 / 2768 0913 Fax : 2768 0912

Fax : 6703 1658

Fax : 2768 0912

KILITCH DRUGS (INDIA) LIMITED

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2014


Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN. L24239MH1992PLC066718

Rs. In Lacs

PART I	Particulars	Three Months Ended			Year ended
		6/30/2014	3/31/2014	6/30/2013	3/31/2014
Sr. No.		Unaudited	Audited	Unaudited	Audited
1	Income from operations	556.04	633.57	368.66	1421.49
	(a) Net Sales/income from operations(net of Excise)	14.66	(20.31)	0.00	60.31
	(b) Other operating income				
	Total income from Operations (Net)	570.70	613.26	368.66	1489.80
2	Expenses	152.92	406.34	237.67	774.77
	(a) Cost of materials consumed				
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	115.33	25.76	(44.04)	(145.96)
	(c) Employee Benefit Expenses	78.94	90.08	60.80	285.76
	(d) Depreciation and Amortisation Expenses	52.81	44.94	33.08	143.97
	(e) Export Product Registration Charges	47.92	111.87	0.00	183.18
	(f) Other Expenses	161.63	363.01	109.52	770.89
	Total Expenses	609.64	1042.00	397.03	2012.62
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(38.84)	(428.74)	(28.37)	(522.82)
4	Other Income	66.19	174.86	210.52	629.12
5	Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)	27.34	(253.88)	182.15	106.30
6	Finance Costs	0.00	0.00	6.18	0.00
7	Profit / (Loss) from ordinary activities before exceptional items (5-6)	27.34	(253.88)	175.97	106.30
8	Exceptional Items	0.00	0.00	0.00	0.00
9	Profit / (Loss) from ordinary activities before tax (7+8)	27.34	(253.88)	175.97	106.30
10	Tax Expenses				
	Current Tax	0.00	(60.00)	0.00	0.00
	Deferred Tax	(22.50)	(8.34)	0.00	(10.35)
	Tax Adjustments of Earlier years	0.00	(1.00)		(1.00)
11	Net Profit / (Loss) from ordinary activities after tax (9-10)	49.84	(184.54)	175.97	117.65
12	Extra Ordinary Items (net of tax expenses)	0.00	0.00	0.00	0.00
13	Net Profit / (Loss) for the period (11+12)	49.84	(184.54)	175.97	117.65
14	Paid-Up equity share capital (Face Value Rs 10 per share)	1323.18	1323.18	1323.18	1323.18
15	Reserve excluding Revaluation Reserve [As per the latest Audited Balance Sheet]				10689.65
16.I	Earnings per share (before extra ordinary items) (F.V. of Rs.10/-each) (not annualised):				
	(a) Basic	0.38	(1.39)	1.33	0.89
	(b) Diluted	0.38	(1.39)	1.31	0.89
16.II	Earnings per share (after extra ordinary items) (F.V. of Rs.10/-each) (not annualised):				
	(a) Basic	0.38	(1.39)	1.33	0.89
	(b) Diluted	0.38	(1.39)	1.31	0.89



PART II	Particulars	Three Months Ended			Year ended
		6/30/2014	3/31/2014	6/30/2013	3/31/2014
A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding				
	a) Number of shares	4697655	4697655	4706393	4697655
	b) Percentage of shareholding	35.50	35.50	35.57	35.50
2	Promoters and Promoter Group Shareholding				
	a) Pledge / Encumbered				
	Number of shares				
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)				
	Percentage of shares (as a % of the total share capital of the company)				
	b) Non-encumbered				
	Number of shares	8534173	8534173	8525435	8534173
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100	100	100	100
	Percentage of shares (as a % of the total share capital of the company)	64.50	64.50	64.43	64.50

B	INVESTOR COMPLAINTS	
	Pending at the beginning of the Quarter	NIL
	Received during the quarter	7
	Disposed off during the quarter	7
	Remaining unresolved at the end of the quarter	NIL

Notes:


1 The above results as reviewed by the audit committee have been taken on record by the Board of Directors at their meeting held on 14th August, 2014.

2 During the quarter, the Company has operated only in one reportable segment i.e. Pharmaceuticals.

3 The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods. The Figures of the last quarter of previous financial year are the balancing figures between audited figures in respect of the full previous financial year and published year to date figures upto the third quarter of the previous financial year.

4 Consequent to the enactment of the Companies Act, 2013 (the Act) and its applicability for the accounting year with effect from 1st April, 2014, the company has computed depreciation with reference to the estimated economic lives of fixed assets prescribed by the Schedule II to the Act or actual useful life. For the assets, whose life has been completed as above, the written down value net of residual value as at April 1, 2014 has been adjusted to retained earnings and in other cases the carrying value as at 1st April, 2014 has been depreciated over the remaining useful life of the assets and accordingly recognised in the above financial results.

Place: Mumbai
Date: 14th August, 2014



Mukund P Mehta
Managing Director

A.M.GHELANI & COMPANY**CHARTERED ACCOUNTANTS****AJIT M. GHELANI***B.Com.(Hons), F.C.A., GRAD. C.W.A.***CHINTAN A. GHELANI***B.Com.(Hons), F.C.A., C.S.*

To,

The Board of Directors


KILITCH DRUGS (INDIA) LIMITED**LIMITED REVIEW REPORT OF THE UNAUDITED STANDALONE RESULTS OF
KILITCH DRUGS (INDIA) LIMITED FOR THE QUARTER ENDED 30.06.2014**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. Kilitch Drugs (India) Limited** for the quarter ended 30th June, 2014, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards notified pursuant to the Companies (Accounting Standards) Rules, 2006 with the General Circular 15/2013 dated 13/09/2013 of the Ministry of Corporate Affairs in respect of section 133 of the Companies Act, 2013 and other recognized accounting practices and policies generally accepted in India has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **A. M. Ghelani & Company**

Chartered Accountants

(Firm Registration No. 103173W)

**Chintan A. Ghelani**

Partner

Membership No. 104391



Place: Mumbai

Date: 14-08-2014

Enclosed : Unaudited financial results for the quarter ended 30th June, 2014 of **M/s. Kilitch Drugs (India) Limited**.